Recent developments include leadership transitions in MDB's board of directors and strategic activities related to its PatentVest subsidiary, including plans for an IPO and release of industry reports.

• MDB Capital Holdings announced transitions in its board of directors in February 2026 [N1].
• PatentVest released a report on the intellectual property battle shaping the $1.8 trillion space economy in January 2026 [N2].
• MDB Capital Holdings announced plans for the PatentVest IPO in August 2025 [N3].
• PatentVest unveiled a comprehensive report on the future of surgical robotics in July 2025 [N4].
• MDB Capital Holdings announced leadership changes in its board of directors in June 2025 [N5].
• MDB Capital Holdings hosted webinars discussing first quarter 2025 results and full year 2024 results in May and March 2025 respectively [N6][N7].
• PatentVest released reports on the competitive landscape of AI-driven data centers and the evolving continuous glucose monitoring market in March and January 2025 respectively [N8].

MDB Capital Holdings leverages a unique public venture capital approach that integrates financing, management, and intellectual property services to support early-stage technology companies. Its structured Big Idea Pipeline and investment criteria enable disciplined selection of high-potential startups. The company's community-driven model fosters long-term investor engagement, which may enhance capital availability and company support. MDB's track record of founding and successfully taking companies public, including recent IPOs, demonstrates its capability to create value. The expansion of its self-clearing broker-dealer operations and the planned PatentVest IPO represent strategic milestones that could enhance its platform and market presence.

MDB Capital Holdings operates in a competitive and complex public venture capital space with limited financial history and reported net losses, which may challenge its ability to sustain operations and fund partner companies. The company's reliance on regulatory compliance for its broker-dealer subsidiary and exposure to changes in U.S. tariffs, trade policies, and government funding pose operational risks. The absence of key-man insurance for principal officers introduces potential leadership continuity risks. Market volatility and the early-stage nature of its partner companies may result in unpredictable financial performance and valuation fluctuations. The success of its business model depends on its ability to identify suitable partner companies and maintain investor community engagement, which is not guaranteed.

MDB Capital Holdings' moat lies in its integrated public venture capital model that combines early-stage company founding, capital provision, and long-term community investor engagement. Its subsidiaries provide complementary services including broker-dealer financing and intellectual property strategy, creating a holistic platform for technology company development. The company's disciplined Big Idea Pipeline and investment criteria focus on disruptive technologies with strong IP and market potential, which supports its ability to identify and nurture promising startups. MDB's history of successfully founding and taking companies public, along with ongoing involvement post-IPO, further strengthens its competitive position. The community of sophisticated investors and entrepreneurs adds a network effect that supports partner companies' growth and capital access.

• Regulatory and Compliance Risks: MDB's broker-dealer subsidiary is subject to extensive regulatory requirements and ongoing reviews, with potential fines or sanctions impacting operations [S1].
• Market and Economic Risks: Changes in U.S. tariffs, trade policies, and government funding may adversely affect MDB's business and its partner companies' ability to operate and raise capital [S2].
• Financial Performance Risks: The company reported a net loss of $21.245 million for fiscal year 2025 and has limited revenue disclosure, indicating financial challenges in sustaining operations and funding growth [S1].
• Key Personnel Risks: MDB does not maintain key-man insurance for its principal officers, which could affect business continuity if key executives depart [S1].
• Competitive Risks: MDB faces competition from traditional venture capital firms, investment banks, and other funds with greater resources and brand recognition [S1].
• Operational Risks: Self-clearing operations expose MDB to operational, technology, liquidity, and financing risks that could disrupt business and increase expenses [S1].

• MDB Capital Holdings, LLC operates as a foundational platform specializing in financing startups, partnering with co-founders, and fostering value creation through a group of companies serving as a unified platform [S1].
• Public Ventures, LLC, a wholly-owned subsidiary operating under the d/b/a 'MDB Capital', is a self-clearing broker-dealer focusing on community-driven micro and small-cap financings, enabling companies to scale through initial financing stages from $5 million to $60 million and facilitating IPOs typically valued between $20 million and $50 million [S1].
• PatentVest, Inc., another group company, provides integrated intellectual property solutions and IP strategy development, acting as a strategic law firm to guide technology companies and curate opportunities for MDB and Public Ventures [S1].
• MDB Minnesota One, Inc (M1), a partner company created in mid-2024, focuses on developing a small molecule anti-senescence platform targeting age-related diseases through treatment of senescent cells; it is currently in pre-clinical development and undertaking feasibility studies [S1].
• MDB uses a 'Big Idea Pipeline' process to identify and vet new technology initiatives, starting from about 250 technologies annually, narrowing to about 50 active Big Idea Companies, with approximately 10 reaching advanced evaluation stages and currently two in active negotiations for partnership or investment [S1].
• Investment criteria for partner companies include tech leadership potential, platform technology applicability, early inflection point for commercialization, clear market insertion, large market potential, and strong intellectual property position [S1].
• MDB acts as founder and initial capital provider for partner companies, typically providing seed capital and first round funding between $5 million and $10 million, with plans to raise additional capital up to $20 to $60 million overall, including public offerings or alternative value realization methods [S1].
• MDB maintains a community of over 500 sophisticated investors, entrepreneurs, and micro/small-cap market participants who support the public venture model and may assist in company development and financing [S1].
• MDB's business model is described as 'public venture capital', differing from traditional venture capital by focusing on early-stage public companies with category-defining technology platforms and fostering long-term investor community engagement [S1].
• MDB has a history of founding and conducting IPOs for companies such as Provention Bio, Cue BioPharma, Pulse Biosciences, and more recently eXoZymes Inc, with ongoing involvement post-IPO through board membership and strategic advice [S1].
• Public Ventures began self-clearing U.S. equity securities in 2024, requiring compliance with SEC, FINRA, DTCC, and NSCC regulations, and maintaining capital and operational capacity to meet regulatory requirements [S1].
• MDB reported cash and cash equivalents of $13.217 million as of December 31, 2025, and a net loss of $21.245 million for the fiscal year 2025 [S1].
• MDB does not disclose revenue figures in the latest filings and has limited financial history as a reorganized holding company [S1].
• MDB faces risks related to changes in U.S. tariffs, import/export regulations, and government funding policies that may affect its operations and those of its partner companies [S2].
• MDB does not maintain key-man insurance for its principal officers, which could impact business continuity if key personnel depart [S1].
• MDB's broker-dealer subsidiary is subject to ongoing regulatory reviews and must maintain compliance with financial responsibility and client protection rules [S1].
• Recent news includes leadership transitions in the board of directors and plans for PatentVest IPO, as well as PatentVest releasing reports on IP battles in the space economy and surgical robotics [N1][N2][N3][N4][N5].